Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2022-09-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于参加湖南辖区上市公司2022年投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement about the company's participation in an investor online collective reception day event organized by regulatory and industry bodies. It includes details about the event date, time, and participants from the company but does not contain any financial data, report content, or voting results. The document length is only 623 characters, indicating it is a brief announcement rather than a full report or transcript. It is not a report publication announcement since it does not mention any report release. It is not a call transcript or earnings release as it is a notice of an upcoming event. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement related to investor relations activities.
2022-09-22 Chinese
湖南启元律师事务所关于圣湘生物科技股份有限公司实际控制人增持公司股份的法律意见书
Regulatory Filings
2022-09-16 Chinese
圣湘生物科技股份有限公司关于实际控制人兼董事长增持股份结果的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the completion of a share increase plan by the company's actual controller and chairman. It details the number of shares increased, the percentage of total shares, and compliance with regulatory requirements. There are no financial statements or detailed financial performance data. The document is a formal disclosure of a director's personal share transactions (increase in shareholding). This fits the definition of Director's Dealing (DIRS). The document length is short and focused solely on shareholding changes by a director, confirming the classification.
2022-09-15 Chinese
圣湘生物科技股份有限公司关于自愿披露相关产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of obtaining a medical device registration certificate for a specific product. It details the product registration information, its intended use, impact on the company, and risk warnings. There is no financial data, no mention of annual or quarterly reports, no voting results, no management changes, no legal proceedings, no capital updates, and no earnings information. The document is a regulatory announcement about product certification and its business impact, typical of a general regulatory filing. The document length is short (1143 characters), and it is not a report or presentation but an announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-09-13 Chinese
圣湘生物科技股份有限公司简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled '简式权益变动报告书' which translates to 'Simplified Equity Change Report'. It details the reduction of shareholding by 安徽志道投资有限公司 in 圣湘生物科技股份有限公司, including dates, share quantities, methods of share disposal (such as centralized bidding and block trades), and the resulting shareholding percentages. The document includes legal statements, declarations, and detailed tables about shareholding changes. It is a formal report of a change in major shareholding, specifically a reduction below 5%. There is no indication that this is an announcement of a report publication or a certification. The content matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. Therefore, the correct classification is MRQ with high confidence.
2022-08-30 Chinese
圣湘生物科技股份有限公司关于持股5%以上股东权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement from 圣湘生物科技股份有限公司 regarding a change in shareholding by a shareholder holding more than 5% of the company's shares. It details the reduction in shareholding percentage, the shareholder's information, the nature of the share transactions, and confirms that the change does not affect control of the company. The document references compliance with securities laws and prior announcements of share reduction plans. There are no financial statements or detailed financial performance data, nor is this a report or presentation. The content fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2022-08-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.